Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorIsala
About this trial
This study is an interventional, explorative, prospective study to show whether shortening of infusion times for patients using nivolumab, pembrolizumab, ipilimumab, trastuzumab, bevacizumab, durvalumab or atezolizumab continues to be associated with an acceptable safety profile.
Infusion times will be gradually shortened if tolerability allowes.
Eligibility criteria
Qualifiers
Starting treatment with monoclonal antibodies: nivolumab, pembrolizumab ipilimumab, bevacizumab, trastuzumab, durvalumab or atezolizumab.
18 years and older.
No known history of increased susceptibility to immunological reactions.
Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.
Disqualifiers
Other research medication within 4 weeks of the start of the study.
Inclusion in medical research in which the administration of medication should follow its stated times and dosages of infusions
Dosage deviates from standard protocol
Patients whom receive drugs through a central venous catheter (and for example porth-a-cath).
Trial design
Treatments tested in this trial
- Nivolumab
- Pembrolizumab
- Ipilimumab
- Durvalumab
- Atezolizumab
- Bevacizumab
- Trastuzumab
- Rituximab
Treatment groups
776 Participants
are divided into 8 treatment groups8
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov